Healthcare · Biotechnology
Price
$0.31
Market Cap
$1.1M
Employees
21
Beta
1.17
Avg Volume
27,705,301
CEO
Thomas K. Equels
Business Description
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.04
Stock Price: $0.31
EPS (Diluted): -8.62
EPS (Diluted): -8.62
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
-0.19
Stock Price: $0.31
Total Equity: -$9.78M
Shares: 1,618,617
Total Equity: -$9.78M
Shares: 1,618,617
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
0.01
Market Cap: $1.06M
Total Debt: $4.73M
Cash: $931,000
EBITDA: -$12.94M
Total Debt: $4.73M
Cash: $931,000
EBITDA: -$12.94M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$5.8M
Market Cap: $1.06M
Total Debt: $4.73M
Cash: $931,000
Total Debt: $4.73M
Cash: $931,000
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
20.78
Stock Price: $0.31
Revenue: $88,000
Shares: 1,618,617
Revenue: $88,000
Shares: 1,618,617
EV/Sales (Total value vs revenue — works when P/E can't)
API65.84
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
-284.1%
Gross Profit: -$250,000
Revenue: $88,000
Revenue: $88,000
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-11,961.4%
Operating Income: -$10.53M
Revenue: $88,000
Revenue: $88,000
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-15,861.4%
Net Income: -$13.96M
Revenue: $88,000
Revenue: $88,000
ROE (Profit from shareholder equity)
APINet Income / Total Equity
261.8%
Net Income: -$13.96M
Total Equity: -$9.78M
Total Equity: -$9.78M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-152.1%
Operating Income: -$10.53M
Tax Rate: 0.0%
Equity: -$9.78M
Total Debt: $4.73M
Cash: $931,000
Tax Rate: 0.0%
Equity: -$9.78M
Total Debt: $4.73M
Cash: $931,000
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.53
Current Assets: $3.30M
Current Liabilities: $6.22M
Current Liabilities: $6.22M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
-0.48
Short-Term Debt: $3.80M
Long-Term Debt: $927,000
Total Debt: $4.73M
Total Equity: -$9.78M
Long-Term Debt: $927,000
Total Debt: $4.73M
Total Equity: -$9.78M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.05
Revenue: $88,000
Shares: 1,618,617
Shares: 1,618,617
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$-6.04
Total Equity: -$9.78M
Shares: 1,618,617
Shares: 1,618,617
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-7.00
Operating CF: -$10.96M
CapEx: -$378,000
Shares: 1,618,617
CapEx: -$378,000
Shares: 1,618,617
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $0.31
Stock Price: $0.31
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$13.96M
Net Income: -$13.96M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares AIM against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 22, 2026 1:36pm (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $135,000 | $141,000 | $202,000 | $170,000 | $88,000 |
| Cost of Revenue | $850,000 | $0 | $42,000 | $31,000 | $338,000 |
| Gross Profit | $-715,000 | $141,000 | $160,000 | $139,000 | $-250,000 |
| Operating Expenses | $18.1M | $20.1M | $32.1M | $19.9M | $10.3M |
| Operating Income | -$18.8M | -$19.9M | -$31.9M | -$19.8M | -$10.5M |
| Net Income | -$19.1M | -$19.4M | -$29.0M | -$17.3M | -$14.0M |
| EBITDA | -$18.3M | -$19.2M | -$28.7M | -$16.5M | -$12.9M |
| EPS | $-14.67 | $-14.69 | $-21.64 | $-11.22 | $-8.62 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 22, 2026 1:36pm (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $32.1M | $27.1M | $5.4M | $1.7M | $931,000 |
| Total Current Assets | $50.2M | $36.3M | $14.6M | $4.2M | $3.3M |
| Total Assets | $57.7M | $40.5M | $19.4M | $8.6M | $5.8M |
| Current Liabilities | $673,000 | $1.4M | $8.7M | $9.5M | $6.2M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $927,000 |
| Total Liabilities | $820,000 | $2.0M | $9.1M | $9.9M | $15.6M |
| Total Equity | $56.9M | $38.5M | $10.2M | -$1.3M | -$9.8M |
| Retained Earnings | -$361.1M | -$380.5M | -$409.5M | -$426.8M | -$440.8M |
Cash Flow (Annual)
Last updated: Jun 22, 2026 1:36pm (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$14.0M | -$16.1M | -$21.3M | -$14.9M | -$11.0M |
| Capital Expenditure | $-633,000 | $-271,000 | $-585,000 | $-18,000 | $-378,000 |
| Free Cash Flow | -$14.6M | -$16.4M | -$21.9M | -$14.9M | -$11.3M |
| Acquisitions (net) | $592,000 | $3.9M | $47,000 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$6.4M | -$5.0M | -$21.6M | -$3.7M | $1.3M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 5:10am (4h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$100,000 $85,057 – $114,942
|
$51.0M $43.4M – $58.7M
|
$74,454 $63,328 – $85,579
|
$24.3M $20.7M – $28.0M
|
| EBITDA |
$-100,000 $-114,942 – $-85,057
|
-$51.0M -$58.7M – -$43.4M
|
$-74,454 $-85,579 – $-63,328
|
-$24.3M -$28.0M – -$20.7M
|
| Net Income |
-$1.1M -$1.4M – $-919,455
|
-$1.2M -$1.4M – $-952,071
|
$-971,170 -$1.2M – $-782,520
|
$161,861 $130,419 – $193,311
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 22, 2026 1:36pm (4d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +4.4% | +43.3% | -15.8% | -48.2% |
| Gross Profit Growth | +119.7% | +13.5% | -13.1% | -279.9% |
| Operating Income Growth | -5.8% | -60.2% | +38.0% | +46.8% |
| Net Income Growth | -1.7% | -48.9% | +40.2% | +19.4% |
| EBITDA Growth | -4.9% | -49.7% | +42.6% | +21.5% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 5:10am (4h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-03-12 | Equels Thomas K | C-Conversion | 25,000.00 | $0.00 | $0 |
| 2026-03-12 | Equels Thomas K | C-Conversion | 25.00 | $0.00 | $0 |
| 2026-03-12 | CHEMEROW DAVID I. | C-Conversion | 25,000.00 | $0.00 | $0 |
| 2026-03-12 | CHEMEROW DAVID I. | C-Conversion | 25.00 | $0.00 | $0 |
| 2026-03-06 | Equels Thomas K | J-Other | 50,000.00 | $1.00 | $50,000 |
| 2026-03-06 | Equels Thomas K | J-Other | 25.00 | $1,000.00 | $25,000 |
| 2026-03-06 | CHEMEROW DAVID I. | J-Other | 50,000.00 | $1.00 | $50,000 |
| 2026-03-06 | CHEMEROW DAVID I. | J-Other | 25.00 | $1,000.00 | $25,000 |
| 2026-02-05 | CHEMEROW DAVID I. | A-Award | 2,800.00 | $1.23 | $3,444 |
| 2025-07-17 | KELLNER TED D | 0.00 | $0.00 | $0 | |
| 2025-06-13 | Equels Thomas K | P-Purchase | 107.00 | $7.70 | $824 |
| 2025-06-12 | Equels Thomas K | P-Purchase | 103.00 | $8.70 | $896 |
| 2025-04-11 | MITCHELL WILLIAM M | P-Purchase | 196,851.00 | $0.03 | $5,000 |
| 2025-04-11 | Equels Thomas K | P-Purchase | 1,968,504.00 | $0.03 | $50,000 |
| 2025-04-11 | KELLNER TED D | P-Purchase | 1,968,504.00 | $0.03 | $50,000 |
| 2025-04-04 | Equels Thomas K | P-Purchase | 41,000.00 | $0.06 | $2,583 |
| 2025-04-04 | Rodino Peter W III | P-Purchase | 500.00 | $0.09 | $44 |
| 2025-03-14 | MITCHELL WILLIAM M | A-Award | 44,899.00 | $0.12 | $5,208 |
| 2025-03-14 | BRYAN NANCY | A-Award | 44,899.00 | $0.12 | $5,208 |
| 2025-03-14 | CHEMEROW DAVID I. | A-Award | 44,899.00 | $0.12 | $5,208 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for AIM — it's generated by the pipeline (
market-narrative step).
No community reviews yet for AIM.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30